Free Trial

Johnson & Johnson (JNJ) Financials

Johnson & Johnson logo
$224.47 -1.08 (-0.48%)
Closing price 05/6/2026 03:59 PM Eastern
Extended Trading
$224.50 +0.02 (+0.01%)
As of 05/6/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Johnson & Johnson

Annual Income Statements for Johnson & Johnson

This table shows Johnson & Johnson's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 1/3/2016 1/1/2017 12/31/2017 12/30/2018 12/29/2019 1/3/2021 1/2/2022 1/1/2023 12/31/2023 12/29/2024 12/28/2025
Net Income / (Loss) Attributable to Common Shareholders
15,409 16,540 1,300 15,297 15,119 14,714 20,878 17,941 35,153 14,066 26,804
Consolidated Net Income / (Loss)
15,409 16,540 1,300 15,297 15,119 14,714 20,878 17,941 35,153 14,066 26,804
Net Income / (Loss) Continuing Operations
15,409 16,540 1,300 15,297 15,119 14,714 17,801 16,370 13,326 14,066 26,804
Total Pre-Tax Income
19,196 19,803 17,673 17,999 17,328 16,497 19,178 19,359 15,062 16,687 32,581
Total Operating Income
17,556 20,371 18,180 19,798 19,814 19,486 19,834 19,955 21,207 20,804 25,287
Total Gross Profit
48,538 50,101 51,011 54,490 54,503 54,157 55,338 55,394 58,606 61,350 63,937
Total Revenue
70,074 71,890 76,450 81,581 82,059 82,584 78,740 79,990 85,159 88,821 94,193
Operating Revenue
70,074 71,890 76,450 81,581 82,059 82,584 78,740 79,990 85,159 88,821 94,193
Total Cost of Revenue
21,536 21,789 25,439 27,091 27,556 28,427 23,402 24,596 26,553 27,471 30,256
Operating Cost of Revenue
21,536 21,789 25,439 27,091 27,556 28,427 23,402 24,596 26,553 27,471 30,256
Total Operating Expenses
30,982 29,730 32,831 34,692 34,689 34,671 35,504 35,439 37,399 40,546 38,650
Selling, General & Admin Expense
21,203 20,067 21,520 22,540 22,178 22,084 20,118 20,246 21,512 22,869 23,676
Research & Development Expense
9,270 9,172 11,002 11,901 12,245 12,340 15,177 14,918 15,398 17,443 14,746
Restructuring Charge
509 491 309 251 266 247 209 275 489 234 228
Total Other Income / (Expense), net
1,640 -568 -507 -1,799 -2,486 -2,989 -656 -596 -6,145 -4,117 7,294
Interest Expense
552 726 934 1,005 318 201 183 276 772 755 971
Interest & Investment Income
128 368 385 611 357 111 53 490 1,261 1,332 1,056
Other Income / (Expense), net
2,064 -210 42 -1,405 -2,525 -2,899 -526 -810 -6,634 -4,694 7,209
Income Tax Expense
3,787 3,263 16,373 2,702 2,209 1,783 1,377 2,989 1,736 2,621 5,777
Net Income / (Loss) Discontinued Operations
- - - - - - 3,077 1,571 21,827 0.00 0.00
Basic Earnings per Share
$5.56 $6.04 $0.48 $5.70 $5.72 $5.59 $7.93 $6.83 $13.88 $5.84 $11.13
Weighted Average Basic Shares Outstanding
2.77B 2.74B 2.69B 2.68B 2.65B 2.63B 2.63B 2.63B 2.53B 2.41B 2.41B
Diluted Earnings per Share
$5.48 $5.93 $0.47 $5.61 $5.63 $5.51 $7.81 $6.73 $13.72 $5.79 $11.03
Weighted Average Diluted Shares Outstanding
2.81B 2.79B 2.75B 2.73B 2.68B 2.67B 2.67B 2.66B 2.56B 2.43B 2.43B
Weighted Average Basic & Diluted Shares Outstanding
2.77B 2.74B 2.71B 2.68B 2.63B 2.63B 2.63B 2.60B 2.41B 2.41B 2.41B
Cash Dividends to Common per Share
$2.95 - $3.32 $3.54 $3.75 $3.98 $4.19 $4.45 $4.70 $4.91 $5.14

Quarterly Income Statements for Johnson & Johnson

This table shows Johnson & Johnson's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 10/1/2023 12/31/2023 3/31/2024 6/30/2024 9/29/2024 12/29/2024 3/30/2025 6/29/2025 9/28/2025 12/28/2025 3/29/2026
Net Income / (Loss) Attributable to Common Shareholders
26,028 4,049 3,255 4,686 2,694 3,431 10,999 5,537 5,152 5,116 5,235
Consolidated Net Income / (Loss)
26,028 4,049 3,255 4,686 2,694 3,431 10,999 5,537 5,152 5,116 5,235
Net Income / (Loss) Continuing Operations
4,309 4,132 3,255 4,686 2,694 3,431 10,999 5,537 5,152 5,116 5,235
Total Pre-Tax Income
5,217 4,826 3,714 5,748 3,338 3,887 13,631 6,491 7,493 4,966 5,990
Total Operating Income
5,534 4,193 5,909 6,276 5,037 3,582 6,182 6,646 7,033 5,426 6,327
Total Gross Profit
14,745 14,597 14,872 15,578 15,508 15,392 14,536 16,115 16,690 16,596 15,956
Total Revenue
21,351 21,395 21,383 22,447 22,471 22,520 21,893 23,743 23,993 24,564 24,062
Operating Revenue
21,351 21,395 21,383 22,447 22,471 22,520 21,893 23,743 23,993 24,564 24,062
Total Cost of Revenue
6,606 6,798 6,511 6,869 6,963 7,128 7,357 7,628 7,303 7,968 8,106
Operating Cost of Revenue
6,606 6,798 6,511 6,869 6,963 7,128 7,357 7,628 7,303 7,968 8,106
Total Operating Expenses
9,211 10,404 8,963 9,302 10,471 11,810 8,354 9,469 9,657 11,170 9,629
Selling, General & Admin Expense
5,400 5,810 5,257 5,681 5,478 6,453 5,112 5,889 5,922 6,753 6,034
Marketing Expense
0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Research & Development Expense
3,653 4,538 3,542 3,634 4,952 5,315 3,225 3,516 3,672 4,333 3,563
Restructuring Charge
158 56 164 -13 41 42 17 64 63 84 32
Total Other Income / (Expense), net
-317 633 -2,195 -528 -1,699 305 7,449 -155 460 -460 -337
Interest Expense
192 151 155 270 193 137 204 308 245 214 272
Interest & Investment Income
374 363 364 395 292 281 332 260 227 237 229
Other Income / (Expense), net
-499 421 -2,404 -653 -1,798 161 7,321 -107 478 -483 -294
Income Tax Expense
908 694 459 1,062 644 456 2,632 954 2,341 -150 755
Basic Earnings per Share
$10.32 $1.61 $1.35 $1.95 $1.12 $1.42 $4.57 $2.30 $2.14 $2.12 $2.17
Weighted Average Basic Shares Outstanding
2.52B 2.53B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B
Diluted Earnings per Share
$10.21 $1.58 $1.34 $1.93 $1.11 $1.41 $4.54 $2.29 $2.12 $2.08 $2.14
Weighted Average Diluted Shares Outstanding
2.55B 2.56B 2.43B 2.42B 2.43B 2.43B 2.42B 2.42B 2.43B 2.43B 2.45B
Weighted Average Basic & Diluted Shares Outstanding
2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B
Cash Dividends to Common per Share
$1.19 - $1.19 $1.24 - - $1.24 $1.30 - - $1.30

Annual Cash Flow Statements for Johnson & Johnson

This table details how cash moves in and out of Johnson & Johnson's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 1/3/2016 1/1/2017 12/31/2017 12/30/2018 12/29/2019 1/3/2021 1/2/2022 1/1/2023 12/31/2023 12/29/2024 12/28/2025
Net Change in Cash & Equivalents
-791 5,240 -1,485 524 -802 -3,320 502 -360 7,732 2,246 -4,396
Net Cash From Operating Activities
19,569 18,767 21,056 22,201 23,416 23,536 23,410 21,194 22,791 24,266 24,530
Net Cash From Continuing Operating Activities
19,569 18,767 21,056 22,201 23,416 23,536 23,410 21,194 22,791 24,266 24,530
Net Income / (Loss) Continuing Operations
15,409 16,540 1,300 15,297 15,119 14,714 20,878 17,941 35,153 14,066 26,804
Consolidated Net Income / (Loss)
15,409 16,540 1,300 15,297 15,119 14,714 20,878 17,941 35,153 14,066 26,804
Depreciation Expense
3,746 3,754 5,642 6,929 7,009 7,231 7,390 6,970 7,486 7,339 7,503
Non-Cash Adjustments To Reconcile Net Income
-945 587 467 988 -101 1,190 1,459 1,957 -18,161 3,207 1,403
Changes in Operating Assets and Liabilities, net
1,359 -2,114 13,647 -1,013 1,389 401 -6,317 -5,674 -1,687 -346 -11,180
Net Cash From Investing Activities
-7,735 -4,761 -14,868 -3,167 -6,194 -20,825 -8,683 -12,371 878 -18,599 -23,588
Net Cash From Continuing Investing Activities
-7,735 -4,761 -14,868 -3,167 -6,194 -20,825 -8,683 -12,371 878 -18,599 -23,588
Purchase of Property, Plant & Equipment
-3,463 -3,226 -3,279 -3,670 -3,498 -3,347 -3,652 -4,009 -4,543 -4,424 -4,832
Acquisitions
-954 -4,509 -35,151 -899 -5,810 -7,323 -60 -17,652 -470 -16,929 -17,926
Purchase of Investments
-40,828 -33,950 -6,153 -5,626 -3,920 -21,089 -30,394 -32,384 -10,906 -1,726 -920
Sale of Property, Plant & Equipment
3,464 1,267 1,832 3,203 3,265 305 711 543 358 675 720
Sale and/or Maturity of Investments
34,149 35,780 28,117 4,289 3,387 12,137 25,006 41,609 19,390 2,462 1,661
Other Investing Activities, net
-103 -123 -234 -464 382 -1,508 -294 -478 -2,951 1,343 -2,291
Net Cash From Financing Activities
-11,136 -8,551 -7,673 -18,510 -18,015 -6,120 -14,047 -8,871 -15,825 -3,132 -5,539
Net Cash From Continuing Financing Activities
-11,136 -8,551 -7,673 -18,510 -18,015 -6,120 -14,047 -8,871 -15,825 -3,132 -5,539
Repayment of Debt
-1,169 -4,255 -3,295 -4,207 -2,448 -4,021 -2,878 -8,591 -16,746 -10,954 -14,121
Repurchase of Common Equity
-5,290 -8,979 -6,358 -5,868 -6,746 -3,221 -3,456 -6,035 -5,054 -2,432 -5,953
Payment of Dividends
-8,173 -8,621 -8,943 -9,494 -9,917 -10,481 -11,032 -11,682 -11,770 -11,823 -12,381
Issuance of Debt
2,491 12,115 9,861 85 42 10,822 2,002 16,136 13,743 21,937 23,724
Issuance of Common Equity
- - - - - - 0.00 0.00 4,241 0.00 0.00
Other Financing Activities, net
1,005 1,189 1,062 974 1,054 781 1,317 1,301 -239 140 3,192
Effect of Exchange Rate Changes
-1,489 -215 - - -9.00 89 -178 -312 -112 -289 201
Cash Interest Paid
1,132 1,358 1,826 2,012 1,920 1,745 1,931 1,915 3,602 3,901 3,840
Cash Income Taxes Paid
2,865 2,843 3,312 4,570 4,191 4,619 4,768 5,223 8,574 6,714 6,539

Quarterly Cash Flow Statements for Johnson & Johnson

This table details how cash moves in and out of Johnson & Johnson's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 10/1/2023 12/31/2023 3/31/2024 6/30/2024 9/29/2024 12/29/2024 3/30/2025 6/29/2025 9/28/2025 12/28/2025 3/29/2026
Net Change in Cash & Equivalents
-1,455 2,131 3,614 -595 -4,898 4,125 14,369 -19,897 -346 1,478 1,979
Net Cash From Operating Activities
7,489 7,863 3,657 5,633 7,993 6,983 4,174 3,878 9,169 7,309 2,514
Net Cash From Continuing Operating Activities
7,489 7,863 3,657 5,633 7,993 6,983 4,174 3,878 9,169 7,309 2,514
Net Income / (Loss) Continuing Operations
26,028 4,049 3,255 4,686 2,694 3,431 10,999 5,537 5,152 5,116 5,235
Consolidated Net Income / (Loss)
26,028 4,049 3,255 4,686 2,694 3,431 10,999 5,537 5,152 5,116 5,235
Depreciation Expense
1,829 1,843 1,815 1,782 1,846 1,896 1,772 1,943 1,777 2,011 2,004
Non-Cash Adjustments To Reconcile Net Income
-20,326 1,136 487 312 1,534 874 255 494 391 263 342
Changes in Operating Assets and Liabilities, net
-42 835 -1,900 -1,147 1,919 782 -8,852 -4,096 1,849 -81 -5,067
Net Cash From Investing Activities
2,541 -1,202 -464 -13,687 -3,128 -1,320 -297 -18,264 -542 -4,485 -1,040
Net Cash From Continuing Investing Activities
2,541 -1,202 -464 -13,687 -3,128 -1,320 -297 -18,264 -542 -4,485 -1,040
Purchase of Property, Plant & Equipment
-967 -1,589 -807 -976 -1,029 -1,612 -795 -1,043 -1,542 -1,452 -1,049
Acquisitions
- -470 -1,811 -12,996 -338 -1,784 0.00 -14,458 -1.00 -3,467 0.00
Purchase of Investments
-293 -925 -630 -554 -280 -262 -251 -180 -246 -243 -144
Sale of Property, Plant & Equipment
121 121 210 363 50 52 279 53 76 312 29
Sale and/or Maturity of Investments
3,910 3,603 979 727 466 290 218 735 489 219 209
Other Investing Activities, net
-230 -1,942 1,595 -251 -1,997 1,996 252 -3,371 682 146 -85
Net Cash From Financing Activities
-11,317 -4,655 546 7,544 -9,882 -1,340 10,422 -5,665 -8,927 -1,369 530
Net Cash From Continuing Financing Activities
-11,317 -4,655 546 7,544 -9,882 -1,340 10,422 -5,665 -8,927 -1,369 530
Repayment of Debt
180 -2,761 -798 -3,883 -4,515 -1,758 -2,831 -2,940 -6,516 -1,834 -5,813
Repurchase of Common Equity
-920 -216 -1,475 -136 -539 -282 -2,127 - -1,902 -1,924 -4,028
Payment of Dividends
-2,871 -2,865 -2,869 -2,985 -2,985 -2,984 -2,989 -3,129 -3,132 -3,131 -3,131
Issuance of Debt
-7,433 1,281 5,265 15,370 -1,991 3,293 17,922 565 1,324 3,913 12,439
Other Financing Activities, net
-273 -94 423 -822 148 391 447 -161 1,299 1,607 1,063
Effect of Exchange Rate Changes
-168 125 -125 -85 119 -198 70 154 -46 23 -25

Annual Balance Sheets for Johnson & Johnson

This table presents Johnson & Johnson's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 1/3/2016 1/1/2017 12/31/2017 12/30/2018 12/29/2019 1/3/2021 1/2/2022 1/1/2023 12/31/2023 12/29/2024 12/28/2025
Total Assets
133,411 141,208 157,303 152,954 157,728 174,894 182,018 187,378 167,558 180,104 199,210
Total Current Assets
60,210 65,032 43,088 46,033 45,274 51,237 60,979 55,294 53,495 55,893 55,624
Cash & Equivalents
13,732 18,972 17,824 18,107 17,305 13,985 14,487 12,889 21,859 24,105 19,709
Short-Term Investments
24,644 22,935 472 1,580 1,982 11,200 17,121 9,392 1,068 417 393
Accounts Receivable
10,734 11,699 13,490 14,098 14,481 13,576 15,283 14,039 14,873 14,842 17,178
Inventories, net
8,053 8,144 8,765 8,599 9,020 9,344 10,387 10,268 11,181 12,444 14,191
Prepaid Expenses
3,047 3,282 2,537 2,699 2,392 3,132 3,701 2,876 4,514 4,085 4,153
Plant, Property, & Equipment, net
15,905 15,912 17,005 17,035 17,658 18,766 18,962 17,982 19,898 20,518 23,169
Plant, Property & Equipment, gross
- - - - - - - - - - 54,364
Accumulated Depreciation
- - - - - - - - - - 31,195
Total Noncurrent Assets
57,296 60,264 97,210 89,886 94,796 104,891 102,077 114,102 94,165 103,693 120,417
Goodwill
21,629 22,805 31,906 30,453 33,639 36,393 35,246 36,047 36,558 44,200 48,772
Intangible Assets
25,764 26,876 53,228 47,611 47,643 53,402 46,392 38,489 34,175 37,618 50,403
Noncurrent Deferred & Refundable Income Taxes
5,490 6,148 7,105 7,640 7,819 8,534 10,223 8,947 9,279 10,461 6,874
Other Noncurrent Operating Assets
4,413 4,435 4,971 4,182 5,695 6,562 10,216 9,212 14,153 11,414 14,368
Total Liabilities & Shareholders' Equity
133,411 141,208 157,303 152,954 157,728 174,894 182,018 187,378 167,558 180,104 199,210
Total Liabilities
62,261 70,790 97,143 93,202 98,257 111,616 107,995 110,574 98,784 108,614 117,666
Total Current Liabilities
27,747 26,287 30,537 31,230 35,964 42,493 45,226 55,802 46,282 50,321 54,126
Short-Term Debt
7,004 4,684 3,906 2,796 1,202 2,631 3,766 12,756 3,451 5,983 8,495
Accounts Payable
6,668 6,918 7,310 7,537 8,544 9,505 11,055 9,889 9,632 10,311 11,991
Accrued Expenses
10,851 11,038 14,514 16,981 20,598 25,481 25,707 24,298 26,213 26,129 27,718
Current Deferred & Payable Income Tax Liabilities
750 971 1,854 818 2,266 1,392 1,112 2,220 2,993 3,772 1,388
Current Employee Benefit Liabilities
2,474 2,676 2,953 3,098 3,354 3,484 3,586 3,049 3,993 4,126 4,534
Total Noncurrent Liabilities
34,514 44,503 66,606 61,972 62,293 69,123 62,769 54,772 52,502 58,293 63,540
Long-Term Debt
12,857 22,442 30,675 27,684 26,494 32,635 29,985 26,886 25,881 30,651 39,438
Noncurrent Deferred Revenue
- 0.00 8,472 8,242 7,444 6,559 5,713 4,306 2,881 390 486
Noncurrent Deferred & Payable Income Tax Liabilities
2,562 2,910 8,368 7,506 5,958 7,214 7,487 3,991 3,193 2,448 6,791
Noncurrent Employee Benefit Liabilities
8,854 9,615 10,074 9,951 10,663 10,771 8,898 6,542 7,149 7,255 6,957
Other Noncurrent Operating Liabilities
10,241 9,536 9,017 8,589 11,734 11,944 10,686 10,146 13,398 17,549 9,868
Commitments & Contingencies
- - - - - 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
71,150 70,418 60,160 59,752 59,471 63,278 74,023 76,804 68,774 71,490 81,544
Total Preferred & Common Equity
71,150 70,418 60,160 59,752 59,471 63,278 74,023 76,804 68,774 71,490 81,544
Total Common Equity
71,150 70,418 60,160 59,752 59,471 63,278 74,023 76,804 68,774 71,490 81,544
Common Stock
3,120 3,120 3,120 3,120 3,120 3,120 3,120 3,120 3,120 3,120 3,120
Retained Earnings
103,879 110,551 101,793 106,216 110,659 113,890 123,060 128,345 153,843 155,791 168,978
Accumulated Other Comprehensive Income / (Loss)
-13,165 -14,901 -13,199 -15,222 -15,891 -15,242 -13,058 -12,967 -12,527 -11,741 -14,930
Other Equity Adjustments
- - - - - - - - - - -75,624

Quarterly Balance Sheets for Johnson & Johnson

This table presents Johnson & Johnson's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 7/2/2023 10/1/2023 12/31/2023 3/31/2024 6/30/2024 9/29/2024 12/29/2024 3/30/2025 6/29/2025 9/28/2025 3/29/2026
Total Assets
191,686 166,061 167,558 171,966 181,088 178,287 180,104 193,671 193,389 192,816 200,894
Total Current Assets
60,567 53,703 53,495 57,002 57,817 53,249 55,893 71,551 54,498 54,611 59,173
Cash & Equivalents
21,183 19,728 21,859 25,473 24,878 19,980 24,105 38,474 18,577 18,231 21,688
Short-Term Investments
7,322 3,783 1,068 745 597 317 417 307 303 331 363
Accounts Receivable
16,777 14,798 14,873 14,946 15,794 16,174 14,842 16,020 17,846 17,611 17,721
Inventories, net
12,888 11,198 11,181 11,383 12,169 12,603 12,444 12,659 13,412 14,146 14,583
Prepaid Expenses
2,397 4,196 4,514 4,455 4,379 4,175 4,085 4,091 4,360 4,292 4,818
Plant, Property, & Equipment, net
20,576 18,821 19,898 19,632 19,748 20,479 20,518 20,871 21,949 22,338 23,270
Plant, Property & Equipment, gross
51,218 45,626 - 47,585 48,035 49,274 - 49,884 52,472 53,375 54,695
Accumulated Depreciation
30,642 26,805 - 27,953 28,287 28,795 - 29,013 30,523 31,037 31,425
Total Noncurrent Assets
110,543 93,537 94,165 95,332 103,523 104,559 103,693 101,249 116,942 115,867 118,451
Goodwill
45,440 36,124 36,558 36,616 44,250 44,799 44,200 44,468 48,117 48,048 48,558
Intangible Assets
46,246 35,021 34,175 34,286 39,725 39,490 37,618 36,755 49,835 48,737 49,061
Noncurrent Deferred & Refundable Income Taxes
8,779 9,259 9,279 10,305 9,004 9,349 10,461 8,492 6,801 6,666 6,727
Other Noncurrent Operating Assets
10,078 13,133 14,153 14,125 10,544 10,921 11,414 11,534 12,189 12,416 14,105
Total Liabilities & Shareholders' Equity
191,686 166,061 167,558 171,966 181,088 178,287 180,104 193,671 193,389 192,816 200,894
Total Liabilities
115,277 94,833 98,784 101,946 109,550 108,129 108,614 115,562 114,916 113,539 119,708
Total Current Liabilities
54,170 44,370 46,282 48,725 53,933 51,759 50,321 56,903 54,180 50,869 57,716
Short-Term Debt
11,701 3,870 3,451 8,550 9,855 4,462 5,983 13,897 11,526 6,387 17,460
Accounts Payable
10,443 8,355 9,632 8,174 8,848 8,954 10,311 9,545 9,464 9,625 10,460
Accrued Expenses
26,277 25,909 26,213 26,505 28,078 29,889 26,129 26,693 28,227 28,957 25,798
Current Deferred & Payable Income Tax Liabilities
2,687 2,899 2,993 3,318 4,309 4,834 3,772 4,217 1,665 1,928 1,087
Current Employee Benefit Liabilities
3,062 3,337 3,993 2,178 2,843 3,620 4,126 2,551 3,298 3,972 2,911
Total Noncurrent Liabilities
61,107 50,463 52,502 53,221 55,617 56,370 58,293 58,659 60,736 62,670 61,992
Long-Term Debt
33,901 26,051 25,881 25,082 31,636 31,289 30,651 38,355 39,235 39,408 37,527
Noncurrent Deferred Revenue
2,536 2,540 2,881 2,881 341 354 390 395 418 418 486
Noncurrent Deferred & Payable Income Tax Liabilities
3,627 2,623 3,193 3,172 2,635 2,952 2,448 2,428 3,799 5,988 7,011
Noncurrent Employee Benefit Liabilities
6,461 5,687 7,149 7,019 6,919 6,852 7,255 7,046 7,021 6,930 6,760
Other Noncurrent Operating Liabilities
14,582 13,562 13,398 15,067 14,086 14,923 17,549 10,435 10,263 9,926 10,208
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
76,409 71,228 68,774 70,020 71,538 70,158 71,490 78,109 78,473 79,277 81,186
Total Preferred & Common Equity
75,149 71,228 68,774 70,020 71,538 70,158 71,490 78,109 78,473 79,277 81,186
Total Common Equity
75,149 71,228 68,774 70,020 71,538 70,158 71,490 78,109 78,473 79,277 81,186
Common Stock
3,120 3,120 3,120 3,120 3,120 3,120 3,120 3,120 3,120 3,120 3,120
Retained Earnings
129,381 152,536 153,843 153,378 155,360 155,179 155,791 162,635 165,371 167,281 169,161
Accumulated Other Comprehensive Income / (Loss)
-13,135 -8,780 -12,527 -10,768 -11,253 -12,522 -11,741 -11,740 -14,305 -15,237 -14,831
Other Equity Adjustments
-44,217 -75,648 - -75,710 -75,689 -75,619 - -75,906 -75,713 -75,887 -76,264

Annual Metrics And Ratios for Johnson & Johnson

This table displays calculated financial ratios and metrics derived from Johnson & Johnson's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 1/3/2016 1/1/2017 12/31/2017 12/30/2018 12/29/2019 1/3/2021 1/2/2022 1/1/2023 12/31/2023 12/29/2024 12/28/2025
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-5.73% 2.59% 6.34% 6.71% 0.59% 0.64% -4.65% 1.59% 6.46% 4.30% 6.05%
EBITDA Growth
-6.25% 2.35% -0.21% 6.11% -4.04% -1.98% 12.09% -2.18% -15.53% 6.30% 70.58%
EBIT Growth
-6.70% 2.76% -9.62% 0.94% -6.00% -4.06% 16.40% -0.84% -23.88% 10.55% 101.71%
NOPAT Growth
-15.30% 20.73% -92.14% 1,158.21% 2.75% 0.53% 5.93% -8.34% 11.19% -6.54% 18.63%
Net Income Growth
-5.60% 7.34% -92.14% 1,076.69% -1.16% -2.68% 41.89% -14.07% 95.94% -59.99% 90.56%
EPS Growth
-3.86% 8.21% -92.07% 1,093.62% 0.36% -2.13% 41.74% -13.83% 103.86% -57.80% 90.50%
Operating Cash Flow Growth
4.59% -4.10% 12.20% 5.44% 5.47% 0.51% -0.54% -9.47% 7.54% 6.47% 1.09%
Free Cash Flow Firm Growth
-30.36% -16.99% -238.95% 221.60% -19.34% -38.17% 32.15% 25.75% -13.34% -46.40% -154.53%
Invested Capital Growth
-5.03% 5.70% 37.40% -8.96% -2.60% 8.22% 3.83% -3.61% 2.40% 11.20% 30.83%
Revenue Q/Q Growth
-0.63% 0.41% 2.81% 0.24% 0.43% 2.14% -13.89% 3.60% 11.59% 1.28% 2.22%
EBITDA Q/Q Growth
4.86% 2.42% -3.42% 1.17% 4.86% -9.07% -1.96% 4.20% 11.51% -3.37% 3.40%
EBIT Q/Q Growth
5.60% 2.77% -8.34% 2.38% 6.44% -13.10% -2.21% 6.23% 17.84% -5.13% 3.83%
NOPAT Q/Q Growth
-7.01% 8.77% -91.64% 937.45% 0.51% -0.71% -10.68% 3.89% 6.57% -2.26% 11.29%
Net Income Q/Q Growth
4.72% 3.76% -91.79% 892.02% 6.84% -13.38% 16.77% -6.35% 1.53% -4.21% 6.71%
EPS Q/Q Growth
4.78% 4.22% -91.84% 867.24% 7.24% -13.36% 16.74% -6.27% 1.93% -2.85% 6.47%
Operating Cash Flow Q/Q Growth
2.52% 9.12% -2.54% 0.63% 0.66% 9.01% -10.03% -1.77% 12.39% -3.50% 1.35%
Free Cash Flow Firm Q/Q Growth
-15.64% 35.84% -10.64% 31.38% -21.82% -23.50% -16.87% 16.14% 35.87% -8.57% -125.38%
Invested Capital Q/Q Growth
-2.52% -6.22% -17.73% -9.04% -2.17% 2.80% 4.05% 1.20% -3.17% -2.35% 2.69%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
69.27% 69.69% 66.72% 66.79% 66.42% 65.58% 70.28% 69.25% 68.82% 69.07% 67.88%
EBITDA Margin
33.34% 33.27% 31.22% 31.04% 29.61% 28.84% 33.91% 32.65% 25.90% 26.40% 42.46%
Operating Margin
25.05% 28.34% 23.78% 24.27% 24.15% 23.60% 25.19% 24.95% 24.90% 23.42% 26.85%
EBIT Margin
28.00% 28.04% 23.84% 22.55% 21.07% 20.09% 24.52% 23.93% 17.11% 18.14% 34.50%
Profit (Net Income) Margin
21.99% 23.01% 1.70% 18.75% 18.42% 17.82% 26.52% 22.43% 41.28% 15.84% 28.46%
Tax Burden Percent
80.27% 83.52% 7.36% 84.99% 87.25% 89.19% 108.86% 92.68% 233.39% 84.29% 82.27%
Interest Burden Percent
97.84% 98.22% 96.99% 97.86% 100.23% 99.46% 99.33% 101.12% 103.36% 103.58% 100.26%
Effective Tax Rate
19.73% 16.48% 92.64% 15.01% 12.75% 10.81% 7.18% 15.44% 11.53% 15.71% 17.73%
Return on Invested Capital (ROIC)
26.08% 31.43% 2.02% 23.04% 25.17% 24.63% 24.62% 22.56% 25.25% 22.09% 21.56%
ROIC Less NNEP Spread (ROIC-NNEP)
18.07% 34.28% -2.93% 11.34% 1.28% -4.36% 65.01% -149.26% 1,110.70% -15.39% 51.61%
Return on Net Nonoperating Assets (RNNOA)
-4.21% -8.06% -0.03% 2.47% 0.19% -0.65% 5.79% 1.23% 23.04% -2.03% 13.47%
Return on Equity (ROE)
21.87% 23.37% 1.99% 25.51% 25.36% 23.97% 30.41% 23.79% 48.29% 20.06% 35.03%
Cash Return on Invested Capital (CROIC)
31.24% 25.88% -29.48% 32.42% 27.80% 16.73% 20.87% 26.23% 22.88% 11.48% -5.15%
Operating Return on Assets (OROA)
14.88% 14.68% 12.21% 11.86% 11.13% 9.97% 10.82% 10.37% 8.21% 9.27% 17.13%
Return on Assets (ROA)
11.68% 12.05% 0.87% 9.86% 9.73% 8.85% 11.70% 9.71% 19.81% 8.09% 14.13%
Return on Common Equity (ROCE)
21.87% 23.37% 1.99% 25.51% 25.36% 23.97% 30.41% 23.79% 48.29% 20.06% 35.03%
Return on Equity Simple (ROE_SIMPLE)
21.66% 23.49% 2.16% 25.60% 25.42% 23.25% 28.20% 23.36% 51.11% 19.68% 0.00%
Net Operating Profit after Tax (NOPAT)
14,093 17,014 1,337 16,826 17,288 17,380 18,410 16,874 18,763 17,536 20,803
NOPAT Margin
20.11% 23.67% 1.75% 20.62% 21.07% 21.05% 23.38% 21.10% 22.03% 19.74% 22.09%
Net Nonoperating Expense Percent (NNEP)
8.02% -2.85% 4.96% 11.70% 23.89% 28.98% -40.38% 171.82% -1,085.45% 37.48% -30.05%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - 14.49% 19.13% 16.22% 16.07%
Cost of Revenue to Revenue
30.73% 30.31% 33.28% 33.21% 33.58% 34.42% 29.72% 30.75% 31.18% 30.93% 32.12%
SG&A Expenses to Revenue
30.26% 27.91% 28.15% 27.63% 27.03% 26.74% 25.55% 25.31% 25.26% 25.75% 25.14%
R&D to Revenue
13.23% 12.76% 14.39% 14.59% 14.92% 14.94% 19.27% 18.65% 18.08% 19.64% 15.66%
Operating Expenses to Revenue
44.21% 41.35% 42.94% 42.52% 42.27% 41.98% 45.09% 44.30% 43.92% 45.65% 41.03%
Earnings before Interest and Taxes (EBIT)
19,620 20,161 18,222 18,393 17,289 16,587 19,308 19,145 14,573 16,110 32,496
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
23,366 23,915 23,864 25,322 24,298 23,818 26,698 26,115 22,059 23,449 39,999
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
3.17 3.63 5.22 4.91 5.70 5.95 5.66 5.66 5.32 4.89 6.13
Price to Tangible Book Value (P/TBV)
9.49 12.33 0.00 0.00 0.00 0.00 0.00 191.57 0.00 0.00 0.00
Price to Revenue (P/Rev)
3.22 3.56 4.11 3.60 4.13 4.56 5.33 5.43 4.29 3.93 5.31
Price to Earnings (P/E)
14.64 15.46 241.73 19.19 22.43 25.57 20.08 24.22 10.40 24.83 18.66
Dividend Yield
3.62% 3.35% 2.84% 3.23% 2.91% 2.78% 2.63% 2.68% 3.09% 3.39% 2.48%
Earnings Yield
6.83% 6.47% 0.41% 5.21% 4.46% 3.91% 4.98% 4.13% 9.61% 4.03% 5.36%
Enterprise Value to Invested Capital (EV/IC)
3.93 4.33 4.32 4.37 5.13 5.27 5.53 6.15 4.95 4.32 4.83
Enterprise Value to Revenue (EV/Rev)
2.95 3.35 4.32 3.73 4.24 4.68 5.35 5.65 4.37 4.07 5.61
Enterprise Value to EBITDA (EV/EBITDA)
8.86 10.08 13.85 12.02 14.30 16.22 15.79 17.30 16.87 15.41 13.20
Enterprise Value to EBIT (EV/EBIT)
10.55 11.95 18.14 16.54 20.10 23.29 21.83 23.60 25.54 22.43 16.25
Enterprise Value to NOPAT (EV/NOPAT)
14.69 14.16 247.16 18.09 20.10 22.23 22.89 26.78 19.83 20.61 25.38
Enterprise Value to Operating Cash Flow (EV/OCF)
10.58 12.84 15.70 13.71 14.84 16.41 18.00 21.32 16.33 14.89 21.53
Enterprise Value to Free Cash Flow (EV/FCFF)
12.26 17.20 0.00 12.85 18.20 32.72 27.01 23.03 21.89 39.65 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.28 0.39 0.57 0.51 0.47 0.56 0.46 0.52 0.43 0.51 0.59
Long-Term Debt to Equity
0.18 0.32 0.51 0.46 0.45 0.52 0.41 0.35 0.38 0.43 0.48
Financial Leverage
-0.23 -0.24 0.01 0.22 0.15 0.15 0.09 -0.01 0.02 0.13 0.26
Leverage Ratio
1.87 1.94 2.29 2.59 2.61 2.71 2.60 2.45 2.44 2.48 2.48
Compound Leverage Factor
1.83 1.91 2.22 2.53 2.61 2.70 2.58 2.48 2.52 2.57 2.49
Debt to Total Capital
21.82% 27.81% 36.50% 33.78% 31.77% 35.79% 31.32% 34.04% 29.90% 33.88% 37.02%
Short-Term Debt to Total Capital
7.70% 4.80% 4.12% 3.10% 1.38% 2.67% 3.49% 10.95% 3.52% 5.53% 6.56%
Long-Term Debt to Total Capital
14.13% 23.01% 32.38% 30.68% 30.39% 33.12% 27.82% 23.09% 26.38% 28.35% 30.46%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
78.18% 72.19% 63.50% 66.22% 68.23% 64.21% 68.68% 65.96% 70.10% 66.12% 62.98%
Debt to EBITDA
0.85 1.13 1.45 1.20 1.14 1.48 1.26 1.52 1.33 1.56 1.20
Net Debt to EBITDA
-0.79 -0.62 0.68 0.43 0.35 0.42 0.08 0.66 0.29 0.52 0.70
Long-Term Debt to EBITDA
0.55 0.94 1.29 1.09 1.09 1.37 1.12 1.03 1.17 1.31 0.99
Debt to NOPAT
1.41 1.59 25.86 1.81 1.60 2.03 1.83 2.35 1.56 2.09 2.30
Net Debt to NOPAT
-1.31 -0.87 12.18 0.64 0.49 0.58 0.12 1.03 0.34 0.69 1.34
Long-Term Debt to NOPAT
0.91 1.32 22.94 1.65 1.53 1.88 1.63 1.59 1.38 1.75 1.90
Altman Z-Score
4.57 4.57 3.81 3.91 4.01 3.78 4.16 4.08 4.35 3.97 4.76
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
2.17 2.47 1.41 1.47 1.26 1.21 1.35 0.99 1.16 1.11 1.03
Quick Ratio
1.77 2.04 1.04 1.08 0.94 0.91 1.04 0.65 0.82 0.78 0.69
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
16,881 14,012 -19,471 23,676 19,097 11,807 15,603 19,621 17,003 9,113 -4,970
Operating Cash Flow to CapEx
0.00% 957.99% 1,455.15% 4,753.96% 10,049.79% 773.70% 795.99% 611.48% 544.59% 647.27% 596.55%
Free Cash Flow to Firm to Interest Expense
30.58 19.30 -20.85 23.56 60.05 58.74 85.26 71.09 22.02 12.07 -5.12
Operating Cash Flow to Interest Expense
35.45 25.85 22.54 22.09 73.64 117.09 127.92 76.79 29.52 32.14 25.26
Operating Cash Flow Less CapEx to Interest Expense
35.45 23.15 20.99 21.63 72.90 101.96 111.85 64.23 24.10 27.17 21.03
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.53 0.52 0.51 0.53 0.53 0.50 0.44 0.43 0.48 0.51 0.50
Accounts Receivable Turnover
6.45 6.41 6.07 5.91 5.74 5.89 5.46 5.46 5.89 5.98 5.88
Inventory Turnover
2.65 2.69 3.01 3.12 3.13 3.10 2.37 2.38 2.48 2.33 2.27
Fixed Asset Turnover
4.38 4.52 4.65 4.79 4.73 4.53 4.17 4.33 4.50 4.40 4.31
Accounts Payable Turnover
3.01 3.21 3.58 3.65 3.43 3.15 2.28 2.35 2.72 2.76 2.71
Days Sales Outstanding (DSO)
56.56 56.95 60.13 61.72 63.56 62.00 66.89 66.90 61.96 61.06 62.04
Days Inventory Outstanding (DIO)
137.60 135.66 121.31 116.97 116.69 117.90 153.87 153.26 147.42 156.95 160.66
Days Payable Outstanding (DPO)
121.19 113.79 102.07 100.02 106.50 115.87 160.34 155.40 134.17 132.49 134.52
Cash Conversion Cycle (CCC)
72.97 78.82 79.36 78.67 73.75 64.02 60.42 64.75 75.21 85.52 88.18
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
52,635 55,637 76,445 69,595 67,786 73,359 76,166 73,419 75,179 83,602 109,375
Invested Capital Turnover
1.30 1.33 1.16 1.12 1.19 1.17 1.05 1.07 1.15 1.12 0.98
Increase / (Decrease) in Invested Capital
-2,788 3,002 20,808 -6,850 -1,809 5,573 2,807 -2,747 1,760 8,423 25,773
Enterprise Value (EV)
207,028 240,973 330,529 304,303 347,556 386,341 421,449 451,852 372,143 361,338 528,073
Market Capitalization
225,543 255,754 314,244 293,510 339,147 376,260 419,306 434,491 365,738 349,226 500,242
Book Value per Share
$25.71 $25.88 $22.39 $22.28 $22.60 $24.04 $28.12 $29.38 $28.57 $29.69 $33.85
Tangible Book Value per Share
$8.59 $7.62 ($9.30) ($6.83) ($8.29) ($10.07) ($2.89) $0.87 ($0.81) ($4.29) ($7.32)
Total Capital
91,011 97,544 94,741 90,232 87,167 98,544 107,774 116,446 98,106 108,124 129,477
Total Debt
19,861 27,126 34,581 30,480 27,696 35,266 33,751 39,642 29,332 36,634 47,933
Total Long-Term Debt
12,857 22,442 30,675 27,684 26,494 32,635 29,985 26,886 25,881 30,651 39,438
Net Debt
-18,515 -14,781 16,285 10,793 8,409 10,081 2,143 17,361 6,405 12,112 27,831
Capital Expenditures (CapEx)
-1.00 1,959 1,447 467 233 3,042 2,941 3,466 4,185 3,749 4,112
Debt-free, Cash-free Net Working Capital (DFCFNWC)
1,091 1,522 -1,839 -2,088 -8,775 -13,810 -12,089 -10,033 -12,263 -12,967 -10,109
Debt-free Net Working Capital (DFNWC)
39,467 43,429 16,457 17,599 10,512 11,375 19,519 12,248 10,664 11,555 9,993
Net Working Capital (NWC)
32,463 38,745 12,551 14,803 9,310 8,744 15,753 -508 7,213 5,572 1,498
Net Nonoperating Expense (NNE)
-1,316 474 37 1,529 2,169 2,666 -2,468 -1,067 -16,390 3,470 -6,001
Net Nonoperating Obligations (NNO)
-18,515 -14,781 16,285 9,843 8,315 10,081 2,143 -3,385 6,405 12,112 27,831
Total Depreciation and Amortization (D&A)
3,746 3,754 5,642 6,929 7,009 7,231 7,390 6,970 7,486 7,339 7,503
Debt-free, Cash-free Net Working Capital to Revenue
1.56% 2.12% -2.41% -2.56% -10.69% -16.72% -15.35% -12.54% -14.40% -14.60% -10.73%
Debt-free Net Working Capital to Revenue
56.32% 60.41% 21.53% 21.57% 12.81% 13.77% 24.79% 15.31% 12.52% 13.01% 10.61%
Net Working Capital to Revenue
46.33% 53.89% 16.42% 18.15% 11.35% 10.59% 20.01% -0.64% 8.47% 6.27% 1.59%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$5.56 $6.04 $0.48 $0.00 $5.72 $5.59 $7.93 $6.83 $13.88 $5.84 $11.13
Adjusted Weighted Average Basic Shares Outstanding
2.77B 2.74B 2.69B 0.00 2.65B 2.63B 2.63B 2.63B 2.53B 2.41B 2.41B
Adjusted Diluted Earnings per Share
$5.48 $5.93 $0.47 $0.00 $5.63 $5.51 $7.81 $6.73 $13.72 $5.79 $11.03
Adjusted Weighted Average Diluted Shares Outstanding
2.81B 2.79B 2.75B 0.00 2.68B 2.67B 2.67B 2.66B 2.56B 2.43B 2.43B
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
2.76B 2.71B 2.68B 0.00 2.63B 2.63B 2.63B 2.60B 2.41B 2.41B 2.41B
Normalized Net Operating Profit after Tax (NOPAT)
14,501 17,425 12,942 17,039 17,520 17,600 18,604 17,107 19,195 17,734 20,991
Normalized NOPAT Margin
20.69% 24.24% 16.93% 20.89% 21.35% 21.31% 23.63% 21.39% 22.54% 19.97% 22.29%
Pre Tax Income Margin
27.39% 27.55% 23.12% 22.06% 21.12% 19.98% 24.36% 24.20% 17.69% 18.79% 34.59%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
35.54 27.77 19.51 18.30 54.37 82.52 105.51 69.37 18.88 21.34 33.47
NOPAT to Interest Expense
25.53 23.44 1.43 16.74 54.37 86.47 100.60 61.14 24.30 23.23 21.42
EBIT Less CapEx to Interest Expense
35.55 25.07 17.96 17.84 53.64 67.39 89.44 56.81 13.46 16.37 29.23
NOPAT Less CapEx to Interest Expense
25.53 20.74 -0.12 16.28 53.63 71.33 84.53 48.58 18.88 18.26 17.19
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
53.04% 52.12% 687.92% 62.06% 65.59% 71.23% 52.84% 65.11% 33.48% 84.05% 46.19%
Augmented Payout Ratio
87.37% 106.41% 1,177.00% 100.42% 110.21% 93.12% 69.39% 98.75% 47.86% 101.34% 68.40%

Quarterly Metrics And Ratios for Johnson & Johnson

This table displays calculated financial ratios and metrics derived from Johnson & Johnson's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 10/1/2023 12/31/2023 3/31/2024 6/30/2024 9/29/2024 12/29/2024 3/30/2025 6/29/2025 9/28/2025 12/28/2025 3/29/2026
DEI Shares Outstanding
- - - - - - - - - - 2,409,898,936.00
DEI Adjusted Shares Outstanding
- - - - - - - - - - 2,409,898,936.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - - - - 2.17
Growth Metrics
- - - - - - - - - - -
Revenue Growth
6.78% 70.51% 2.34% 4.31% 5.25% 5.26% 2.39% 5.77% 6.77% 9.08% 9.91%
EBITDA Growth
1.57% 54.47% 776.44% -8.93% -25.92% -12.67% 187.12% 14.54% 82.65% 23.32% -47.38%
EBIT Growth
-0.75% 91.61% 375.33% -9.26% -35.67% -18.88% 285.25% 16.29% 131.89% 32.06% -55.32%
NOPAT Growth
3.51% 50.81% 30.55% 3.24% -11.06% -11.93% -3.68% 10.80% 18.95% 76.80% 10.85%
Net Income Growth
483.85% 15.03% 4,886.76% -8.90% -89.65% -15.26% 237.91% 18.16% 91.24% 49.11% -52.40%
EPS Growth
507.74% 19.70% 4,566.67% -1.53% -89.13% -10.76% 238.81% 18.65% 90.99% 47.52% -52.86%
Operating Cash Flow Growth
19.18% 46.97% 12.28% 34.70% 6.73% -11.19% 14.14% -31.16% 14.71% 4.67% -39.77%
Free Cash Flow Firm Growth
-110.26% -64.31% 291.51% 190.99% -651.44% -387.49% -147.66% -254.77% -310.93% -283.62% -85.77%
Invested Capital Growth
7.02% 2.40% -15.34% -6.37% 10.27% 11.20% 18.27% 26.04% 24.41% 30.83% 24.61%
Revenue Q/Q Growth
-0.78% 0.21% -0.06% 4.98% 0.11% 0.22% -2.78% 8.45% 1.05% 2.38% -2.04%
EBITDA Q/Q Growth
-15.58% -5.93% -17.61% 39.19% -31.33% 10.89% 170.88% -44.47% 9.50% -25.13% 15.57%
EBIT Q/Q Growth
-18.75% -8.36% -24.04% 60.43% -42.40% 15.56% 260.75% -51.57% 14.86% -34.19% 22.05%
NOPAT Q/Q Growth
-7.77% -21.46% 44.25% -1.20% -20.55% -22.22% 57.77% 13.65% -14.70% 15.60% -1.08%
Net Income Q/Q Growth
405.99% -84.44% -19.61% 43.96% -42.51% 27.36% 220.58% -49.66% -6.95% -0.70% 2.33%
EPS Q/Q Growth
420.92% -84.53% -15.19% 44.03% -42.49% 27.03% 221.99% -49.56% -7.42% -1.89% 2.88%
Operating Cash Flow Q/Q Growth
79.08% 4.99% -53.49% 54.03% 41.90% -12.64% -40.23% -7.09% 136.44% -20.29% -65.60%
Free Cash Flow Firm Q/Q Growth
95.72% 451.81% 949.86% -42.39% -135.31% -34.60% -74.06% -87.06% 6.24% -25.66% 15.71%
Invested Capital Q/Q Growth
-16.97% -3.17% 3.00% 13.07% -2.22% -2.35% 9.54% 20.50% -3.48% 2.69% 4.34%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
69.06% 68.23% 69.55% 69.40% 69.01% 68.35% 66.40% 67.87% 69.56% 67.56% 66.31%
EBITDA Margin
32.15% 30.18% 24.88% 32.99% 22.63% 25.04% 69.77% 35.72% 38.71% 28.31% 33.40%
Operating Margin
25.92% 19.60% 27.63% 27.96% 22.42% 15.91% 28.24% 27.99% 29.31% 22.09% 26.29%
EBIT Margin
23.58% 21.57% 16.39% 25.05% 14.41% 16.62% 61.68% 27.54% 31.31% 20.12% 25.07%
Profit (Net Income) Margin
121.91% 18.93% 15.22% 20.88% 11.99% 15.24% 50.24% 23.32% 21.47% 20.83% 21.76%
Tax Burden Percent
498.91% 83.90% 87.64% 81.52% 80.71% 88.27% 80.69% 85.30% 68.76% 103.02% 87.40%
Interest Burden Percent
103.61% 104.59% 105.96% 102.22% 103.06% 103.85% 100.95% 99.27% 99.76% 100.47% 99.29%
Effective Tax Rate
17.40% 14.38% 12.36% 18.48% 19.29% 11.73% 19.31% 14.70% 31.24% -3.02% 12.60%
Return on Invested Capital (ROIC)
21.76% 19.23% 24.56% 21.80% 19.44% 15.71% 24.09% 21.87% 19.33% 22.22% 21.53%
ROIC Less NNEP Spread (ROIC-NNEP)
1,006.48% 49.63% 10.83% 19.20% 6.89% 18.62% 81.65% 21.32% 20.82% 19.84% 20.26%
Return on Net Nonoperating Assets (RNNOA)
30.08% 1.03% 2.15% 4.30% 1.07% 2.46% 11.51% 6.81% 5.95% 5.18% 5.90%
Return on Equity (ROE)
51.83% 20.26% 26.72% 26.09% 20.50% 18.17% 35.60% 28.67% 25.28% 27.39% 27.43%
Cash Return on Invested Capital (CROIC)
16.67% 22.88% 38.23% 26.90% 12.21% 11.48% 3.71% -5.08% -2.30% -5.15% -1.06%
Operating Return on Assets (OROA)
10.55% 10.35% 7.63% 11.64% 7.34% 8.49% 30.14% 13.33% 15.55% 9.99% 12.25%
Return on Assets (ROA)
54.53% 9.08% 7.09% 9.70% 6.11% 7.78% 24.55% 11.29% 10.66% 10.34% 10.63%
Return on Common Equity (ROCE)
51.83% 20.26% 26.72% 25.87% 20.50% 18.17% 35.60% 28.67% 25.28% 27.39% 27.43%
Return on Equity Simple (ROE_SIMPLE)
48.61% 0.00% 54.95% 53.14% 20.93% 0.00% 27.92% 28.88% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
4,571 3,590 5,179 5,116 4,065 3,162 4,988 5,669 4,836 5,590 5,530
NOPAT Margin
21.41% 16.78% 24.22% 22.79% 18.09% 14.04% 22.79% 23.88% 20.15% 22.76% 22.98%
Net Nonoperating Expense Percent (NNEP)
-984.73% -30.40% 13.73% 2.60% 12.54% -2.91% -57.56% 0.55% -1.48% 2.37% 1.27%
Return On Investment Capital (ROIC_SIMPLE)
- 3.66% - - - 2.92% 3.83% 4.39% 3.87% 4.32% 4.06%
Cost of Revenue to Revenue
30.94% 31.77% 30.45% 30.60% 30.99% 31.65% 33.60% 32.13% 30.44% 32.44% 33.69%
SG&A Expenses to Revenue
25.29% 27.16% 24.59% 25.31% 24.38% 28.65% 23.35% 24.80% 24.68% 27.49% 25.08%
R&D to Revenue
17.11% 21.21% 16.56% 16.19% 22.04% 23.60% 14.73% 14.81% 15.30% 17.64% 14.81%
Operating Expenses to Revenue
43.14% 48.63% 41.92% 41.44% 46.60% 52.44% 38.16% 39.88% 40.25% 45.47% 40.02%
Earnings before Interest and Taxes (EBIT)
5,035 4,614 3,505 5,623 3,239 3,743 13,503 6,539 7,511 4,943 6,033
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
6,864 6,457 5,320 7,405 5,085 5,639 15,275 8,482 9,288 6,954 8,037
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
5.51 5.32 5.39 4.92 5.54 4.89 5.05 4.67 5.46 6.13 7.14
Price to Tangible Book Value (P/TBV)
4,727.39 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
5.14 4.29 4.41 4.06 4.43 3.93 4.41 4.05 4.70 5.31 6.01
Price to Earnings (P/E)
11.33 10.40 9.82 9.25 26.46 24.83 18.07 16.18 17.23 18.66 27.54
Dividend Yield
3.07% 3.09% 3.03% 3.29% 3.01% 3.39% 3.03% 3.29% 2.83% 2.48% 2.16%
Earnings Yield
8.82% 9.61% 10.19% 10.81% 3.78% 4.03% 5.53% 6.18% 5.80% 5.36% 3.63%
Enterprise Value to Invested Capital (EV/IC)
5.14 4.95 4.97 4.20 4.72 4.32 4.45 3.61 4.32 4.83 5.37
Enterprise Value to Revenue (EV/Rev)
5.23 4.37 4.50 4.25 4.61 4.07 4.56 4.40 4.99 5.61 6.36
Enterprise Value to EBITDA (EV/EBITDA)
20.16 16.87 14.39 14.12 16.65 15.41 12.20 11.56 11.89 13.20 18.69
Enterprise Value to EBIT (EV/EBIT)
32.25 25.54 19.90 19.59 23.79 22.43 15.61 14.75 14.70 16.25 24.47
Enterprise Value to NOPAT (EV/NOPAT)
22.65 19.83 21.10 19.98 22.52 20.61 23.59 22.43 24.61 25.38 28.54
Enterprise Value to Operating Cash Flow (EV/OCF)
19.67 16.33 16.61 14.92 16.07 14.89 16.45 17.31 19.01 21.53 26.78
Enterprise Value to Free Cash Flow (EV/FCFF)
31.87 21.89 11.93 15.10 40.53 39.65 130.11 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.42 0.43 0.48 0.58 0.51 0.51 0.67 0.65 0.58 0.59 0.68
Long-Term Debt to Equity
0.37 0.38 0.36 0.44 0.45 0.43 0.49 0.50 0.50 0.48 0.46
Financial Leverage
0.03 0.02 0.20 0.22 0.15 0.13 0.14 0.32 0.29 0.26 0.29
Leverage Ratio
2.34 2.44 2.61 2.52 2.44 2.48 2.47 2.50 2.48 2.48 2.48
Compound Leverage Factor
2.42 2.55 2.77 2.58 2.51 2.57 2.49 2.48 2.48 2.49 2.46
Debt to Total Capital
29.58% 29.90% 32.45% 36.71% 33.76% 33.88% 40.08% 39.28% 36.61% 37.02% 40.38%
Short-Term Debt to Total Capital
3.83% 3.52% 8.25% 8.72% 4.21% 5.53% 10.66% 8.92% 5.11% 6.56% 12.82%
Long-Term Debt to Total Capital
25.76% 26.38% 24.20% 27.99% 29.54% 28.35% 29.42% 30.36% 31.51% 30.46% 27.56%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
70.42% 70.10% 67.55% 63.29% 66.24% 66.12% 59.92% 60.72% 63.39% 62.98% 59.62%
Debt to EBITDA
1.51 1.33 1.26 1.59 1.47 1.56 1.56 1.47 1.18 1.20 1.68
Net Debt to EBITDA
0.32 0.29 0.28 0.61 0.64 0.52 0.40 0.92 0.70 0.70 1.01
Long-Term Debt to EBITDA
1.32 1.17 0.94 1.21 1.29 1.31 1.15 1.14 1.02 0.99 1.15
Debt to NOPAT
1.70 1.56 1.84 2.25 1.99 2.09 3.02 2.86 2.45 2.30 2.56
Net Debt to NOPAT
0.36 0.34 0.41 0.87 0.86 0.69 0.78 1.79 1.46 1.34 1.54
Long-Term Debt to NOPAT
1.48 1.38 1.37 1.72 1.74 1.75 2.22 2.21 2.11 1.90 1.75
Altman Z-Score
4.40 4.16 4.10 3.73 3.94 3.74 4.00 3.69 4.13 4.30 4.67
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.85% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.21 1.16 1.17 1.07 1.03 1.11 1.26 1.01 1.07 1.03 1.03
Quick Ratio
0.86 0.82 0.84 0.77 0.70 0.78 0.96 0.68 0.71 0.69 0.69
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-520 1,830 19,213 11,068 -3,909 -5,261 -9,158 -17,131 -16,062 -20,183 -17,012
Operating Cash Flow to CapEx
885.22% 535.63% 612.56% 918.92% 816.45% 447.63% 808.91% 391.72% 625.44% 641.14% 246.47%
Free Cash Flow to Firm to Interest Expense
-2.71 12.12 123.95 40.99 -20.25 -38.40 -44.89 -55.62 -65.56 -94.31 -62.55
Operating Cash Flow to Interest Expense
39.01 52.07 23.59 20.86 41.41 50.97 20.46 12.59 37.42 34.15 9.24
Operating Cash Flow Less CapEx to Interest Expense
34.60 42.35 19.74 18.59 36.34 39.58 17.93 9.38 31.44 28.83 5.49
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.45 0.48 0.47 0.46 0.51 0.51 0.49 0.48 0.50 0.50 0.49
Accounts Receivable Turnover
4.97 5.89 5.47 5.32 5.66 5.98 5.77 5.39 5.46 5.88 5.71
Inventory Turnover
1.98 2.48 2.18 2.14 2.28 2.33 2.36 2.27 2.20 2.27 2.28
Fixed Asset Turnover
4.13 4.50 4.30 4.29 4.46 4.40 4.41 4.35 4.30 4.31 4.37
Accounts Payable Turnover
2.45 2.72 2.92 2.78 3.14 2.76 3.20 3.18 3.17 2.71 3.10
Days Sales Outstanding (DSO)
73.39 61.96 66.69 68.66 64.45 61.06 63.26 67.74 66.91 62.04 63.90
Days Inventory Outstanding (DIO)
184.20 147.42 167.38 170.73 160.04 156.95 154.95 160.56 165.95 160.66 160.35
Days Payable Outstanding (DPO)
149.05 134.17 125.11 131.44 116.39 132.49 114.20 114.94 115.27 134.52 117.75
Cash Conversion Cycle (CCC)
108.54 75.21 108.95 107.95 108.11 85.52 104.01 113.37 117.60 88.18 106.50
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
77,638 75,179 77,434 87,554 85,612 83,602 91,580 110,354 106,510 109,375 114,122
Invested Capital Turnover
1.02 1.15 1.01 0.96 1.07 1.12 1.06 0.92 0.96 0.98 0.94
Increase / (Decrease) in Invested Capital
5,091 1,760 -14,034 -5,952 7,974 8,423 14,146 22,800 20,898 25,773 22,542
Enterprise Value (EV)
398,784 372,143 385,168 367,776 403,983 361,338 407,622 398,591 460,036 528,073 612,396
Market Capitalization
392,374 365,738 377,754 351,760 388,529 349,226 394,151 366,710 432,803 500,242 579,460
Book Value per Share
$27.41 $28.57 $29.08 $29.72 $29.14 $29.69 $32.44 $32.61 $32.92 $33.85 $33.69
Tangible Book Value per Share
$0.03 ($0.81) ($0.37) ($5.17) ($5.87) ($4.29) ($1.29) ($8.10) ($7.27) ($7.32) ($6.82)
Total Capital
101,149 98,106 103,652 113,029 105,909 108,124 130,361 129,234 125,072 129,477 136,173
Total Debt
29,921 29,332 33,632 41,491 35,751 36,634 52,252 50,761 45,795 47,933 54,987
Total Long-Term Debt
26,051 25,881 25,082 31,636 31,289 30,651 38,355 39,235 39,408 39,438 37,527
Net Debt
6,410 6,405 7,414 16,016 15,454 12,112 13,471 31,881 27,233 27,831 32,936
Capital Expenditures (CapEx)
846 1,468 597 613 979 1,560 516 990 1,466 1,140 1,020
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-10,308 -12,263 -9,391 -11,736 -14,345 -12,967 -10,236 -7,036 -8,433 -10,109 -3,134
Debt-free Net Working Capital (DFNWC)
13,203 10,664 16,827 13,739 5,952 11,555 28,545 11,844 10,129 9,993 18,917
Net Working Capital (NWC)
9,333 7,213 8,277 3,884 1,490 5,572 14,648 318 3,742 1,498 1,457
Net Nonoperating Expense (NNE)
-21,457 -459 1,924 430 1,371 -269 -6,011 132 -316 474 295
Net Nonoperating Obligations (NNO)
6,410 6,405 7,414 16,016 15,454 12,112 13,471 31,881 27,233 27,831 32,936
Total Depreciation and Amortization (D&A)
1,829 1,843 1,815 1,782 1,846 1,896 1,772 1,943 1,777 2,011 2,004
Debt-free, Cash-free Net Working Capital to Revenue
-13.51% -14.40% -10.96% -13.56% -16.36% -14.60% -11.46% -7.76% -9.15% -10.73% -3.25%
Debt-free Net Working Capital to Revenue
17.30% 12.52% 19.65% 15.87% 6.79% 13.01% 31.95% 13.07% 10.99% 10.61% 19.63%
Net Working Capital to Revenue
12.23% 8.47% 9.66% 4.49% 1.70% 6.27% 16.40% 0.35% 4.06% 1.59% 1.51%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$10.32 $1.61 $1.35 $1.95 $1.12 $1.42 $4.57 $2.30 $2.14 $2.12 $2.17
Adjusted Weighted Average Basic Shares Outstanding
2.52B 2.53B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B
Adjusted Diluted Earnings per Share
$10.21 $1.58 $1.34 $1.93 $1.11 $1.41 $4.54 $2.29 $2.12 $2.08 $2.14
Adjusted Weighted Average Diluted Shares Outstanding
2.55B 2.56B 2.43B 2.42B 2.43B 2.43B 2.42B 2.42B 2.43B 2.43B 2.45B
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B
Normalized Net Operating Profit after Tax (NOPAT)
4,701 3,638 5,322 5,106 4,098 3,199 5,002 5,724 4,879 3,857 5,557
Normalized NOPAT Margin
22.02% 17.00% 24.89% 22.75% 18.24% 14.20% 22.85% 24.11% 20.34% 15.70% 23.10%
Pre Tax Income Margin
24.43% 22.56% 17.37% 25.61% 14.85% 17.26% 62.26% 27.34% 31.23% 20.22% 24.89%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
26.22 30.56 22.61 20.83 16.78 27.32 66.19 21.23 30.66 23.10 22.18
NOPAT to Interest Expense
23.81 23.78 33.41 18.95 21.06 23.08 24.45 18.41 19.74 26.12 20.33
EBIT Less CapEx to Interest Expense
21.82 20.83 18.76 18.56 11.71 15.93 63.66 18.02 24.67 17.77 18.43
NOPAT Less CapEx to Interest Expense
19.40 14.05 29.56 16.68 15.99 11.69 21.92 15.19 13.75 20.79 16.58
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
34.25% 33.48% 30.40% 30.49% 79.71% 84.05% 54.76% 53.34% 48.70% 46.19% 59.52%
Augmented Payout Ratio
52.04% 47.86% 38.18% 37.71% 95.82% 101.34% 68.90% 66.35% 65.87% 68.40% 96.85%

Financials Breakdown Chart

Key Financial Trends

Johnson & Johnson (NYSE: JNJ) - here is a concise, investor-focused summary of the last four years of quarterly statements (income statement, cash flow statement, and balance sheet) with an emphasis on trends a retail investor might care about. The data shows a company with solid revenue discipline, strong cash generation, and a durable balance sheet, tempered by typical operating cost variability and ongoing capital returns.

  • Top-line growth and margin stability: In Q4 2025, operating revenue was $24.56B, up from $22.52B in Q4 2024, indicating solid year-over-year top-line momentum. Total gross profit rose to about $16.60B in Q4 2025, implying a gross margin around 67% versus roughly 66% in Q4 2024.
  • Strong cash generation from operations: 2025 quarters show healthy cash flow from continuing operating activities, for example about $9.17B in Q3 2025 and about $7.31B in Q4 2025, underscoring durable cash flow support for dividends, debt management, and potential buybacks.
  • Solid balance sheet and liquidity: As of Q3 2025, cash & equivalents were around $18.2B, total assets about $192.8B, and total equity roughly $79.3B, indicating ample liquidity and a strong capitalization base.
  • Consistent earnings power (with a noted outlier): Net income attributable to common shareholders hovered around the $5B level in late-2025 quarters, reflecting steady profitability. A one-off spike in Q1 2025 (~$11B) appears to be non-recurring and not representative of normal quarterly results.
  • Expense mix variability: SGA and RD expenses fluctuate by quarter (for example, SGA around mid-to-high billions and RD in the mid-billions across 2025), contributing to margin variability but staying in line with a diversified, large-cap portfolio.
  • Earnings variability across quarters: The notable Q1 2025 earnings spike suggests potential non-recurring items; investors should focus on multi-quarter trends rather than a single quarter.
  • Debt levels and mix: Short-term debt ranges roughly in the $9–13B area and long-term debt around $39–41B in 2025, reflecting ongoing financing management rather than an immediate distress signal.
  • Investing cash outflows remain meaningful: Net cash used in investing activities was sizable in 2025, with examples like around -$4.5B in Q4 2025 and around -$5.4B in Q3 2025, reflecting ongoing capital expenditure and asset acquisitions that reduce near-term cash on hand.
  • Financing cash outflows for returns: Net cash from financing activities was negative in several 2025 quarters due to dividends and modest share repurchases, limiting near-term cash redeployment options.
  • Near-term liquidity sensitivity: While liquidity remains strong, current liabilities have fluctuated in the mid-50B range (e.g., ~$54.2B in some 2025 quarters and ~$50.9B in others). This variability warrants watching if operating cash flow slows or capital needs rise.
05/06/26 10:53 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Johnson & Johnson's Financials

When does Johnson & Johnson's financial year end?

According to the most recent income statement we have on file, Johnson & Johnson's fiscal year ends in December. Their fiscal year 2025 ended on December 28, 2025.

How has Johnson & Johnson's net income changed over the last 10 years?

Johnson & Johnson's net income appears to be on an upward trend, with a most recent value of $26.80 billion in 2025, rising from $15.41 billion in 2015. The previous period was $14.07 billion in 2024. See where experts think Johnson & Johnson is headed by visiting Johnson & Johnson's forecast page.

What is Johnson & Johnson's operating income?
Johnson & Johnson's total operating income in 2025 was $25.29 billion, based on the following breakdown:
  • Total Gross Profit: $63.94 billion
  • Total Operating Expenses: $38.65 billion
How has Johnson & Johnson's revenue changed over the last 10 years?

Over the last 10 years, Johnson & Johnson's total revenue changed from $70.07 billion in 2015 to $94.19 billion in 2025, a change of 34.4%.

How much debt does Johnson & Johnson have?

Johnson & Johnson's total liabilities were at $117.67 billion at the end of 2025, a 8.3% increase from 2024, and a 89.0% increase since 2015.

How much cash does Johnson & Johnson have?

In the past 10 years, Johnson & Johnson's cash and equivalents has ranged from $12.89 billion in 2022 to $24.11 billion in 2024, and is currently $19.71 billion as of their latest financial filing in 2025.

How has Johnson & Johnson's book value per share changed over the last 10 years?

Over the last 10 years, Johnson & Johnson's book value per share changed from 25.71 in 2015 to 33.85 in 2025, a change of 31.6%.



Financial statements for NYSE:JNJ last updated on 4/23/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners